Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16352
Full metadata record
DC FieldValueLanguage
dc.contributor.authorThapa, Bibhusal-
dc.contributor.authorWatkins, D Neil-
dc.contributor.authorJohn, Thomas-
dc.date2016-10-06-
dc.date.accessioned2016-10-16T22:44:44Z-
dc.date.available2016-10-16T22:44:44Z-
dc.date.issued2016-10-06-
dc.identifier.citationExpert Review of Anticancer Therapy 2016; online first: 6 Octoberen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/16352-
dc.description.abstractInitial data of immune based therapy showed promise for improving malignant mesothelioma (MM) treatment. However, the results of such treatments have neither been predictable nor consistent and recent clinical studies of immune checkpoint inhibitors in MM have dampened initial enthusiasm. Areas covered: We comprehensively discuss the basis, modalities and updated results of immunotherapy in MM. An online search was conducted for relevant literature and abstracts of recent meetings. Expert commentary: Although initial studies have demonstrated proof of principle that manipulating the immune checkpoint axis holds promise in MM, results of some recent large studies using checkpoint inhibitors have been disappointing. This is not surprising given the low mutational load in MM and suggests that single agent immunotherapy has limited benefit in this disease. We believe that in order to demonstrate durable survival benefits, they will need to be used in combination approaches with other immunotherapies, vaccines or chemotherapy.en
dc.subjectMesotheliomaen
dc.subjectPD-L1en
dc.subjectCheck point inhibitionen
dc.subjectImmunotherapyen
dc.subjectTherapeutic vaccinesen
dc.titleImmunotherapy for malignant mesothelioma: reality checken
dc.typeJournal Articleen
dc.identifier.journaltitleExpert Review of Anticancer Therapyen
dc.identifier.affiliationMedicine (University of Melbourne)en
dc.identifier.affiliationCancer Imuunobiology Lab, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationThe Kinghorn Cancer Center, Garvan Institute of Medical Research, Darlinghurst, NSW, Australiaen
dc.identifier.affiliationMedical Oncologyen
dc.identifier.affiliationSchool of Cancer Medicine, La Trobe University, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationOlivia Newton-John Cancer Wellness and Research Centreen
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/27669108en
dc.identifier.doi10.1080/14737140.2016.1241149en
dc.type.contentTexten
dc.type.austinJournal Articleen_US
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.openairetypeJournal Article-
item.grantfulltextnone-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
crisitem.author.deptThoracic Surgery-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

2
checked on Jan 29, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.